Direct-to-Consumer Genetic Testing Summary of a Workshop (2011) / Chapter Skim
Currently Skimming:
Appendix E: Planning Group Biographies
Appendix E: Planning Group Biographies
Pages 57-70
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 57... ...
He addresses "green" technologies (wind, solar, fuel cell, biofuels) , legal strategies for bringing chemicals to market, a wide variety of Clean Air Act issues, risk assessment and management, greenhouse gas science and international negotiations, chemical regula tion, FDA and EPA food contact and antimicrobial approvals, access to genetic information, and environmental aspects of international trade.
|
From page 58... ...
In 1997, she was named Chief of the Laboratory of Lymphocyte Biology at the National Heart, Lung and Blood Institute at the National Institutes of Health in Bethesda, MD. She served on the Scholars Committee of the Howard Hughes Medical Institute and on the Biomedical Research Training Program for Underrepresented Minorities at NHLBI, where she received the Director's Award in 1999.
|
From page 59... ...
She is on the editorial boards of a number of journals including Current Protocols of Immunology. She is currently a member of the AAMC-AAU Advisory Committee on Financial Conflicts of Interest in Clinical Research, on the National Academies' Committee on Science, Technology and the Law, and on the Secretary's Advisory Committee for Human Research Protections for which she serves as chair.
|
From page 60... ...
Dr. Ganz is also the Director of the Division of Cancer Prevention and Control Research of the Jonsson Comprehensive Cancer Center at UCLA, and leads a large research group that applies the scientific disciplines of public health (epidemiology, health services, behavioral sciences, biostatistics)
|
From page 61... ...
Gishizky supervised the development of capabilities and scientific programs that employ computer simulation models to identify patient pop ulations who would benefit most from new medicines and combination therapies. Use of these capabilities result in faster and more cost-effec tive drug development programs by helping drug developers predict patient responses prior to initiation of therapy, thus helping physicians optimize the beneficial outcome and minimize the risk to the patient.
|
From page 62... ...
The Office was formed in 1997 to assess the impact of advances in human genetics and the Human Genome Project on public health and disease prevention. As the nation's prevention agency, CDC's mission is to protect the health and safety of people, to provide credible information to enhance health decisions, and to promote health through strong partnerships.
|
From page 63... ...
Dr. Korn served on the Boards of Directors of the Stanford University Hospital from October 1982 to April 1995, the Children's Hospital at Stanford from October 1984 to its closure, and the Lucile Salter Packard Children's Hospital at Stanford from October
|
From page 64... ...
He was an Andrew W Mellon post doctoral fellow, holds an honorary doctorate from Hofstra University, and is a recipient of the Benjamin Rush Medal from the Col lege of William and Mary Law School.
|
From page 65... ...
Dr. Mazza has been the study director on numerous Academy reports including Science and Security in a Post - World, 00; Reaping the Benefits of Genomic and Proteomic Research, 00; Intentional Human Dosing Studies for EPA Regulatory Purposes: Scientific and Ethical Issues, 00; Ensuring the Quality of Data Disseminated by the Federal Goernment, 00; The Age of Expert Testimony: Science in the Courtroom, 00; Issues for Science and Engineering Researchers in the Digital Age, 00; and Obserations on the President's Fiscal Year 000 Federal Science and Technology Budget, .
|
From page 66... ...
In the biomedical arena, she has written annual reports for, among others: Human Genome Sci ences, 1993 (the company's first) ; Genetic Therapy Inc.
|
From page 67... ...
Dr. Berger received his doctorate from Emory University in the Biochemistry, Cell and Developmental Biology Program studying the fatal childhood neurodegenerative disorder, Niemann Pick Disease Type C, and additionally performing genome wide screening for novel cellular targets of anti-cancer and antimalarial drug compounds.
|
From page 68... ...
Reports from her most recently completed studies include Genes, Behaior, and the Social Enironment: Moing Beyond the Nature/Nurture Debate, Training Physicians for Public Health Careers, and State of the USA Health Indicators. She is currently Staff Director of the Roundtable on Translating Genomic-Based Research for Health, Staff Director of the Roundtable on Health Lit eracy, and Study Director for the Committee on a National Surveillance System for Cardiovascular and Other Select Chronic Diseases.
|
From page 69... ...
Murphy has also served on numerous editorial boards, including Cancer Research, Clinical Cancer Research, and the Journal of Clinical Oncology. She has been a member of the Boards of Directors of the American Cancer Society, the American Association of Cancer Research, the American Society of Hematology, and the American Society of Clinical Oncology, and has been an advisor to NCI and FDA.
|
From page 70... ...
At IOM, he contributed projects on value in cancer care, health consequences for the uninsured, continuing medical education, and health care data collection practices to improve quality of care and reduce health disparities.
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.